Atea Pharmaceuticals Inc
NASDAQ:AVIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
US |
|
R
|
Rapt Therapeutics Inc
F:0RA
|
US |
|
T
|
Telefonica SA
OTC:TEFOF
|
ES |
|
New Fortress Energy Inc
NASDAQ:NFE
|
US |
|
I
|
Ingredion Inc
XMUN:CNP
|
US |
|
Boyd Group Services Inc
TSX:BYD
|
CA |
|
Bluestone Jewellery and Lifestyle Ltd
NSE:BLUESTONE
|
IN |
|
Stylam Industries Ltd
BSE:526951
|
IN |
|
L
|
Loews Corp
F:LTR
|
US |
|
O
|
Oil and Gas Development Co Ltd
LSE:37OC
|
PK |
|
Arctic Paper SA
STO:ARP
|
PL |
|
Vault Minerals Ltd
F:RKM0
|
AU |
|
E
|
EMCOR Group Inc
SWB:EM4
|
US |
|
JD.Com Inc
HKEX:9618
|
CN |
|
V
|
Vicor Corp
F:VCV
|
US |
|
L
|
Lineage Cell Therapeutics Inc
XBER:BT3
|
US |
|
U
|
Uponor Oyj
LSE:0KI5
|
FI |
|
Robinhood Markets Inc
NASDAQ:HOOD
|
US |
|
V
|
Vicor Corp
XBER:VCV
|
US |
Wall St Price Targets
AVIR Price Targets Summary
Atea Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
AVIR is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AVIR's stock price target?
Price Target
8.16
USD
According to Wall Street analysts, the average 1-year price target for
AVIR is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.